In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

A federal judge blocked parts of HHS's vaccine policy changes, siding with medical groups against Robert F. Kennedy Jr.'s ...

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three ...

March 3 (Reuters) - Moderna (MRNA.O), opens new tab has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences (ROIV.O), opens new tab, and Arbutus Biopharma (ABUS.O), opens new tab up to ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. Moderna will pay $950 million ...

Moderna has filed with the Food and Drug Administration for emergency use authorization for its COVID-19 vaccine for people ages 12 to 17, according to a news release from the company. Moderna's COVID ...